Dublin, April 16, 2019 (GLOBE NEWSWIRE) -- The "Antimicrobial Resistance Diagnostics Market, Strategies & Trends By Pathogen and Technology with Executive Guides and Customization 2018 to 2023" report has been added to ResearchAndMarkets.com's offering.
Diagnostics are leading the charge in reducing the threat posed by antimicrobial resistance. New diagnostic technologies, beyond gene sequencing, are under development to capture this growing market. This report has looked at the technology picture, giving you plain language understanding of the different ways pathogens, and infections can be diagnosed.
The 6 Key Large Pathogen Opportunities in this space have been identified and market forecasts have been developed. The report includes profiles of 20 companies, large and small, working in this area.
Key Topics Covered:
i. Antimicrobial Resistance - Strategic Situation Analysis
ii. Guide for Executives, Marketing, Sales and Business Development Staff
iii. Guide for Management Consultants and Investment Advisors
1. Introduction and Market Definition
1.1 The Growing Threat and Opportunity of Antimicrobial Resistance
1.2 Defining the Opportunity
1.2.1 Revenue Market Size
1.3 Methods and Sources
1.3.1 Authors
1.3.2 Sources
1.4 U.S. Antibiotic Markets - Perspective
1.4.1 U.S. Outpatient Use of Antibiotics
1.4.2 U.S. Pharmaceutical Spending.
2. Overview of a Dynamic Market
2.1 Market Players - Roles & Impacts
2.1.1 Drug manufacturers - Larger/pharmaceutical
2.1.2 Drug manufacturers - Generic
2.1.3 Contract Research and Manufacturing
2.1.4 In Vitro Diagnostics Industry
2.1.5 Drug Marketing Companies
2.1.6 Biotechnology Companies
2.1.7 Regulatory Bodies
2.2 Understanding Antimicrobial Resistance
2.2.1 What is Antimicrobial Resistance (AMR).
2.2.2 Bacteria and Other Microbes
2.2.3 The History of Antibiotics
2.2.4 The Role of Animal Husbandry
2.2.5 The Implications of Horizontal Transfer
2.2.6 The Threat of AMR
2.3 The Changing Road to New Antibiotics & Technologies
2.4 The Key Role of Diagnostics in AMR
3. The Market Opportunity of AMR
3.1 The Key Large Market Opportunities in AMR
3.1.1 Streptococcus Pneumoniae (DRSP)
3.1.2 Campylobacter (DRC)
3.1.3 Clostridium Difficile (CD)
3.1.4 Staphylococcus aureus (MRSA)
3.1.5 Neisseria gonorrhoeae (DRNG)
3.1.6 Salmonella (DRNTS)
3.2 Diagnostic Technology Development Opportunities
3.2.1 What's Wrong with Microbiology
3.2.2 The Features Battleground of Infectious Disease Diagnostics
3.2.3 Multiplex vs. POC/Rapid
3.2.4 The Miracle of Genetics
3.2.5 From Multiple Pathogens to All Pathogens - The Next Next Generation
3.2.6 Gene Sequence Diagnostics WITHOUT the Sequencing.
3.2.7 Markers of Resistance.
3.2.8 What Happens to the Microbiology Lab?
3.4. Antibiotic Resistance Recent Developments
Importance of These Developments
How to Use This Section
Qiagen, Ares Genetics Ink Licensing Pact for AMR Bioinformatics
OpGen to File First 510(k) for AMR Gene Panel
Curetis' Subsidiary Ares Genetics Teams Up with Sandoz in Fight Against AMR
GeneCapture to determine antibiotic sensitivity in an automated rapid portable device
Quick identification of multidrug-resistant pathogens
OpGen to Offer Qiagen Nucleic Acid Purification Tech With Acuitas Pathogen Panel
Metagenomics Enables Researchers to Uncover Drug Resistance Genes
Rapid detection of multi-drug-resistant bacteria
Improved Diagnostics Fail to Halt the Rise of Tuberculosis
High Throughput Manufacturing Lines to Answer Growing Needs for Diagnosis Cartridges
New solution for diagnosing antibiotic-resistant bacteria
MALDI-TOF - Results in Minutes not Days.
CRISPR Tool Used to Uncover Infections
Automated Blood Tests Startup MeMed Raises Funds, Wins Grant
BD, Check-Points Receive CE Mark for Resistant Organism Screening Test
LiDia BSI Detects Pathogens and Antimicrobial Resistance
New tool can Track Resistant Malaria
Rapid Test Developed to Measure Antibiotic Resistance in Patients with UTIs
Longitude Funds for POC Tests
New test can identify dangerous bacteria with resistance to last-resort antibiotic
bioMrieux receives FDA clearance for expanded pathogen identification capability
OpGen Inks Deal to Use Thermo Fisher PCR Tech in Acuitas Gene Panel Tests
Hospital Plumbing Harbors Antibiotic Resistant Bacteria
Acquisition Strategy Fills Out Roche's Diagnostic Pipeline
Curetis Gets Singapore Approval for Pneumonia Test
PlexBio, Denka to Codevelop Sepsis, Multidrug Resistance MDx
Curetis, MGI Collaborate to Combine Sample Prep, NGS Technologies
4. Key Biotechnology Companies and Their Technology
4.1 Diagnostics
4.1.1 1928 Diagnostics
4.1.2 Sense Biodetection.
4.1.3 Fusion Genomics.
4.1.4 Day Zero Diagnostics.
4.1.5 Inflammatix
4.1.6 Hutman Diagnostics
4.1.8 bioMrieux Diagnostics
4.1.9 Curetis N.V. / Curetis GmbH
4.1.10 Great Basin Corporation
4.1.11 Becton, Dickinson and Company
4.1.12 Roche Diagnostics
4.1.13 Cepheid (now Danaher)
4.1.14 Atlas Genetics
4.1.14 Accelerate Diagnostics
4.1.15 Seimens
4.1.16 Abbott Diagnostics
4.1.17 Thermo Fisher
4.1.18 Bio - Rad
4.1.19 GenePOC Diagnostics
4.1.20 Sysmex
4.1.21 Ortho Clinical
5. The Global Market
5.1 Global Market by Country
6. Global Market by Pathogens
6.1 Global Market by Pathogens
6.2 DRSP
6.3 DRC
6.4 CD
6.5 MRSA
6.5 DRNG
6.6 DRNTS
7. AMR Diagnostics by Technology
7.1 Global Market by Technology
7.2 Bacterial Culture
7.3 Immunoassay
7.4 Polymerase Chain Reaction
7.5 Genetic Sequencing
7.6 Mass Spectrometer
7.7 Rapid, POC and Other
8. Vision of the Future of AMR Diagnostics
For more information about this report visit https://www.researchandmarkets.com/r/hed6ug
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.